Format

Send to

Choose Destination
J Intern Med. 2006 Jan;259(1):70-80.

In vitro and in vivo models for testing arrhythmogenesis in drugs.

Author information

1
AstraZeneca R&D Mölndal, Integrative Pharmacology, Mölndal, Sweden. leif.g.carlsson@astrazeneca.com

Abstract

The steadily increasing list of drugs associated with prolongation of the QT interval and torsades de pointes (TdP) constitute a medical problem of major concern. Hence, there is a need at an early stage to identify drug candidates with an inherent capacity to induce repolarization-related proarrhythmias, avoiding exposure of large populations to potentially harmful drugs. Furthermore, the availability of clinically relevant and predictive animal models should reduce the risk that effective and potentially life-saving drugs never reach the market. This review will discuss the pros and cons of some in vivo and in vitro animal models for assessing proarrhythmia liability.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center